CW February 2005
Volume 14Issue Number 2 February 2005 ISSN 10593802 Depot Octreotide Markedly Improves Survival in Patients with Carcinoid SyndromeOctreotide, a somatostatin analog in a slow-release depot form, can nearly double the survival time for patients with carcinoid syndrome, according to a report at the American Society of Clinical Oncology?s annual Gastro-intestinal Cancers Symposium.
Go to Previous Page Go to Next Page Source & Additional Reading L. Anthony, American Society of Clinical Oncology?s annual Gastrointestinal Cancers Symposium. Purchase Downloadable Full-text PDF of Article: $10.00 Subscription is more cost effective than purchasing PDFs on-the-fly. Click here for details. Download Complete Issue CW February 2005Purchase Downloadable Full-text PDF of Complete Issue: $20.00 |
|
Member Login | Home | Offices | Subscribe | Glossary | Cancer Technologies | Contact Us
Adenine Press, 2066 Central Avenue, Schenectady, NY 12304 USA |
Re-initialize IP-based Login |
